World Library  
Flag as Inappropriate
Email this Article

Direct thrombin inhibitor

Article Id: WHEBN0007292635
Reproduction Date:

Title: Direct thrombin inhibitor  
Author: World Heritage Encyclopedia
Language: English
Subject: Discovery and development of direct thrombin inhibitors, Argatroban, Bivalirudin, Dabigatran, Anticoagulant
Publisher: World Heritage Encyclopedia

Direct thrombin inhibitor

Direct thrombin inhibitors (DTIs) are a class of medication that act as anticoagulants (delaying blood clotting) by directly inhibiting the enzyme thrombin (factor II). Some are in clinical use, while others are undergoing clinical development. Several members of the class are expected to replace heparin (and derivatives) and warfarin in various clinical scenarios.


  • Types 1
    • Bivalent 1.1
    • Univalent 1.2
    • Allosteric Inhibitors 1.3
  • Uses 2
  • Monitoring 3
  • See also 4
  • References 5


There are three types of DTIs, dependent on their interaction with the thrombin molecule. Bivalent DTIs (hirudin and analogs) bind both to the active site and exosite 1, while univalent DTIs bind only to the active site.[1] The third class of inhibitors which are gaining importance recently is the allosteric inhibitors.


Hirudin and derivatives were originally discovered in Hirudo medicinalis:


Univalent DTIs include:

Allosteric Inhibitors

Thrombin demonstrates a high level of allosteric regulation.[2] Allosterism in thrombin is regulated by the exosites 1 and 2 and the sodium binding site. A recent patent review has shown that the general consensus among researchers is that allosteric inhibitors may provide a more regulatable anticoagulant.[3] Some of the allosteric inhibitors discovered include DNA aptamers,[3] benzofuran dimers,[4] benzofuran trimers,[5] as well as polymeric lignins.[6] A new sulfated β-O4 lignin (SbO4L) has been discovered which has shown a dual mechanism of action for anti-thrombosis. This SbO4L shows allosteric inhibition of thrombin for fibrinogen, while providing a competitive inhibition of thrombin interaction with platelet glycoprotein Ibα (GPIbα), thereby preventing thrombin mediated platelet aggregation.[7] However, despite the growing interest and the advances in allosterism, no allosteric thrombin inhibitor has still reached the stage of clinical trials.


Bivalent DTIs enjoy limited use in circumstances where heparin would be indicated such as the acute coronary syndrome ("unstable angina"), but cannot be used. As they are administered by injection (intravenous, intramuscular or subcutaneous), they are less suitable for long-term treatment.[1]

Argatroban (as well as the hirudins) is used for heparin-induced thrombocytopenia, a relatively infrequent yet serious complication of heparin treatment that requires anticoagulation (as it increases both arterial and venous thrombosis risk) but not with the putative agent, heparin.[1]

Ximelagatran showed good efficacy compared with warfarin in several trials in prevention and treatment of deep vein thrombosis and as thromboprophylaxis in atrial fibrillation.[1] Development was stopped by manufacturer AstraZeneca, however, because of reports of liver enzyme derangements and liver failure.[8] Recent studies have indicated Dabigatran is slightly more effective for stroke thromboprophylaxis in the setting of atrial fibrillation than coumadin.


There is no therapeutic drug monitoring widely available for DTIs, in contrast with warfarin (INR) and heparin (APTT). The ecarin clotting time, although not in general clinical use, would be the most appropriate monitoring test.[1]

See also


  1. ^ a b c d e Di Nisio M, Middeldorp S, Büller H (2005). "Direct thrombin inhibitors.". N Engl J Med 353 (10): 1028–40.  
  2. ^ Lechtenberg, BC; Freund, SM; Huntington, JA (Sep 2012). "An ensemble view of thrombin allostery.". Biological chemistry 393 (9): 889–98.  
  3. ^ a b Mehta, AY; Jin, Y; Desai, UR (Jan 2014). "An update on recent patents on thrombin inhibitors (2010 - 2013).". Expert opinion on therapeutic patents 24 (1): 47–67.  
  4. ^ Sidhu, PS; Liang, A; Mehta, AY; Abdel Aziz, MH; Zhou, Q; Desai, UR (Aug 11, 2011). "Rational design of potent, small, synthetic allosteric inhibitors of thrombin.". Journal of Medical Chemistry 54 (15): 5522–31.  
  5. ^ Sidhu, PS; Abdel Aziz, MH; Sarkar, A; Mehta, AY; Zhou, Q; Desai, UR (Jun 27, 2013). "Designing allosteric regulators of thrombin. Exosite 2 features multiple subsites that can be targeted by sulfated small molecules for inducing inhibition.". Journal of Medical Chemistry 56 (12): 5059–70.  
  6. ^ Henry, BL; Monien, BH; Bock, PE; Desai, UR (Nov 2, 2007). "A novel allosteric pathway of thrombin inhibition: Exosite II mediated potent inhibition of thrombin by chemo-enzymatic, sulfated dehydropolymers of 4-hydroxycinnamic acids.". The Journal of Biological Chemistry 282 (44): 31891–9.  
  7. ^ Mehta, AY; Thakkar, JN; Mohammed, BM; Martin, EJ; Brophy, DF; Kishimoto, T; Desai, UR (Apr 10, 2014). "Targeting the GPIbα binding site of thrombin to simultaneously induce dual anticoagulant and antiplatelet effects.". Journal of Medical Chemistry 57 (7): 3030–9.  
  8. ^ "AstraZeneca Decides to Withdraw Exanta" (Press release). AstraZeneca. 2006-02-14. Retrieved 2006-05-08. 
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.